DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
March 19, 2019 16:30 ET
|
DiaMedica Therapeutics Inc.
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute ischemic stroke Phase II...
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
March 18, 2019 13:56 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March...
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
March 12, 2019 13:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz...
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
February 14, 2019 08:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic...
Breathtec Announces Name Change to Algernon Pharmaceuticals
February 14, 2019 07:00 ET
|
Breathtec Biomedical Inc.
New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of liver disease (NASH), chronic kidney disease and inflammatory bowel disease. The company's...
Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease
January 21, 2019 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 10:41 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 07:30 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
December 07, 2018 07:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its...
Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
November 28, 2018 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone...